Updated:
Moderna
Moderna is a other based in Cambridge, founded 2010; the Altss profile covers its classification, headquarters, registration, AUM band, and key contacts for...
Moderna
Learn how we’re changing the world of medicine. Discover career opportunities, our product pipeline, and browse media resources. Meet Moderna.
General information
Firm type
other
Year founded
2010
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, MA, United States
Additional offices
Leverkusen · Greenwich · Boston · New York · Seattle · Princeton · San Francisco · Hellerup
Principals
Stéphane Bancel
Chief Executive Officer
Noubar Afeyan
Co-Founder and Chairman
Keke
Senior Director of People Analytics
Sector focus
Frequently asked questions
Who runs investment decisions at Moderna?
Stéphane Bancel is CEO and leads corporate strategy. Board of directors, including co-founder Noubar Afeyan, governs major decisions. No separate investment committee structure is publicly comparable to a family office.
How does Moderna source proprietary deal flow?
Moderna's pipeline is primarily internally developed through its mRNA platform, supplemented by licensing and academic partnerships. The company does not operate a venture capital-style sourcing model.
Is Moderna structured as a single family office or does it operate more like a venture firm?
Moderna is a publicly traded biotechnology company, not a family office. Its founding capital came from venture investors, and it operates as a drug developer and manufacturer.
Does Moderna participate in fund commitments or only direct deals?
Moderna does not function as an investment vehicle. It engages in partnerships and licensing arrangements, such as the collaboration with Merck for cancer vaccine development.
What investment stages does Moderna typically target?
Moderna's development stages are clinical: preclinical through Phase 3 trials. Financial investment stages are not applicable; it is a drug developer, not an allocator.
Which sectors does Moderna explicitly avoid?
Moderna focuses on mRNA-based medicines and does not explicitly state avoidance of sectors, but its pipeline excludes areas like medical devices or diagnostics beyond mRNA.
Where does the underlying wealth come from?
Moderna's wealth generation is primarily from its commercial COVID-19 vaccine sales and equity financing. Founding wealth origins are venture capital, not a family fortune.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: